Details
Singuliar Indications
As additional treatment for bronchial asthma in patients aged 2 to 5 years with persistent asthma mild to moderate degree, which is not controlled by inhaled corticosteroids, as well as inadequate clinical control of asthma using agonists β-adrenergic short-acting, which are used as needed.
As an alternative treatment instead of low-dose inhaled corticosteroids for patients aged 2 to 5 years with persistent asthma, mild, have not noted the many recent serious asthma attacks requiring oral corticosteroids and who can not use inhaled corticosteroids.
Preventing asthma, which is the dominant component of bronchoconstriction induced by exercise in patients aged 2 years.
Relief of symptoms of seasonal and perennial allergic rhinitis.
Contraindications
Hypersensitivity to any component of the drug. Children under 2 years old.
Dosage & Administration
The drug should be used for children under adult supervision.
Patients with asthma and allergic rhinitis (seasonal and perennial) should take 1 tablet 4 mg chewing 1 per day. For the relief of symptoms of allergic rhinitis you receive selected individually.
For asthma treatment dose for children aged 2 to 5 years is 1 chewable tablet (4 mg) a day, in the evening. Synhulyar® be taken 1 hour before meals or 2 hours after meals. No need for dose adjustment in this age group. Synhulyar® drug in dosage form chewable tablets (4 mg) are not recommended for children under 2 years.
